Acadia Pharmaceuticals Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Acadia Pharmaceuticals Inc in the second quarter 2026?
Acadia Pharmaceuticals Inc achieved a return on average equity (ROE) of 32.39 % in its second quarter 2026, this is above ACAD's average return on equity of -36.56%.
Acadia Pharmaceuticals Inc shareholder's equity over the 12 months ending in its second quarter 2026 are valued at $1,175 million

ROE fell compared to the first quarter 2026, despite the net income growth of 766.1% from the first quarter 2026.

Within the Major Pharmaceutical Preparations industry 25 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 229 to 304.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Equity Change	58.88 %	63.1 %	67.49 %	58.92 %	-
Y / Y Net Income Change	18.13 %	-80.84 %	90.32 %	119.07 %	-20.14 %
Net Income (TTM) in Millions	380	376	391	261	222
Return On Equity (TTM)	32.39 %	35.65 %	41.9 %	32.27 %	30.67 %
ACAD's Total Ranking	# 304	# 229	# 0	# 256	# 260
Equity (TTM) in Millions	1,307	1,248	1,227	917	822
Seq. Equity Change	4.69 %	1.68 %	33.81 %	11.54 %	7.47 %
Seq. Net Income Change	766.1 %	-98.67 %	281.13 %	169.18 %	40.44 %

Back to ACAD Management Effectiveness >> ACAD's 5 Years Annual ROE >> Compare ACAD ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 26
Sector	# 54
Overall	# 304

Return On Equity Statistics
High	Average	Low
41.9 %	-36.56 %	-108.46 %
(Dec 31 2025)		(Sep 30 2012)

ACAD Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	1,227	733	432	400	541
Y / Y Equity Change	67.49 %	69.72 %	7.83 %	-25.97 %	-13.73 %
Net Income in Millions	391	226	-61	-216	-168
Y / Y Net Income Change	72.66 %	-	-	-	-
Return On Equity	31.86 %	30.9 %	-14.19 %	-53.94 %	-31.04 %

Back to ACAD Management Effectiveness >> ACAD's 5 Years Annual ROE >> Compare ACAD ROE to its Competitors

Annual Roe Comment

In 2025 ROE improved to 31.86 % compared to the previous year, due to net income growth.

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
ACAD's' Return on Equity at Yahoo Finance
ACAD's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for ACAD's Competitors
Subscribers only: Roe for Acadia Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Equity for ACAD's Customers

Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector	ROE
Q32 Bio Inc	76.88 %
3m Company	76.55 %
Oramed Pharmaceuticals Inc	73.03 %
Tg Therapeutics Inc	72.30 %
Idexx Laboratories Inc	71.96 %
Elite Pharmaceuticals Inc	71.10 %
Zoetis Inc	68.87 %
Rallybio Corporation	68.56 %
Earth Science Tech Inc	66.17 %
Aurinia Pharmaceuticals Inc	59.00 %
Vaxart Inc	53.04 %
Qhslab Inc	51.21 %
Tenet Healthcare Corp	50.64 %
Nrc Health	48.29 %
Concentra Group Holdings Parent Inc	48.13 %
Bristol myers Squibb Company	46.65 %
Agilent Technologies inc	41.99 %
Eton Pharmaceuticals Inc	40.13 %
Adma Biologics Inc	39.59 %
Dexcom Inc	36.25 %
Transmedics Group Inc	33.37 %
Arcutis Biotherapeutics Inc	32.92 %
Caredx Inc	32.81 %
Zevra Therapeutics Inc	32.56 %
Acadia Pharmaceuticals Inc	32.39 %
Pro dex Inc	31.96 %
Protalix Biotherapeutics inc	31.61 %
Illumina Inc	31.08 %
Innoviva Inc	30.03 %
Phibro Animal Health Corporation	29.66 %

Date modified: 2026-09-11T09:45:24+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.